BerGenBio ASA announced the appointment of Martin Olin as new Chief Executive Officer from 8 September 2021. Following twelve years as CEO of BerGenBio, Richard Godfrey has decided to step down as CEO of the Company with immediate effect to pursue other business interests. Rune Skeie, Chief Financial Officer of BerGenBio, will assume the role of interim CEO until 8 September 2021. Mr. Olin brings more than 20 years of executive experience in the pharmaceutical and biotechnology industry to BerGenBio. He previously served as CEO of Symphogen, a biotechnology company focused on the development of protein drugs based on recombinant monoclonal antibody mixtures, acquired by Servier in 2020. Before joining Symphogen in 2012, Mr. Olin was a senior partner with SLS Invest, a Scandinavian based healthcare focused private equity fund. Previously, he held managerial positions in Novo Nordisk including Finance Director, EMEA. Most recently he has served as Managing Partner of Nordic Eye, a Copenhagen based Venture Capital firm.